Fatemeh Chalabianloo

580 total citations
29 papers, 259 citations indexed

About

Fatemeh Chalabianloo is a scholar working on Epidemiology, Pediatrics, Perinatology and Child Health and Psychiatry and Mental health. According to data from OpenAlex, Fatemeh Chalabianloo has authored 29 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 9 papers in Pediatrics, Perinatology and Child Health and 9 papers in Psychiatry and Mental health. Recurrent topics in Fatemeh Chalabianloo's work include Opioid Use Disorder Treatment (8 papers), Hepatitis C virus research (6 papers) and Liver Disease Diagnosis and Treatment (4 papers). Fatemeh Chalabianloo is often cited by papers focused on Opioid Use Disorder Treatment (8 papers), Hepatitis C virus research (6 papers) and Liver Disease Diagnosis and Treatment (4 papers). Fatemeh Chalabianloo collaborates with scholars based in Norway, United Kingdom and Sweden. Fatemeh Chalabianloo's co-authors include Lars Thore Fadnes, Kjell Arne Johansson, Jørn Henrik Vold, Svetlana Skurtveit, Else‐Marie Løberg, Jørgen G. Bramness, Peter Vickerman, Christer Frode, Gudrun Høiseth and Marianne Kristiansen Kringen and has published in prestigious journals such as Scientific Reports, PLoS Medicine and Psychopharmacology.

In The Last Decade

Fatemeh Chalabianloo

25 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fatemeh Chalabianloo Norway 9 95 88 52 51 51 29 259
Jørn Henrik Vold Norway 9 105 1.1× 78 0.9× 22 0.4× 65 1.3× 27 0.5× 38 254
Richard Hallinan Australia 11 157 1.7× 145 1.6× 53 1.0× 104 2.0× 59 1.2× 14 439
Oscar D’Agnone United Kingdom 8 145 1.5× 199 2.3× 63 1.2× 14 0.3× 46 0.9× 15 296
Elise Bailey United States 6 118 1.2× 254 2.9× 70 1.3× 35 0.7× 78 1.5× 7 433
Nuria J. Thusius United States 6 48 0.5× 83 0.9× 26 0.5× 8 0.2× 53 1.0× 9 265
Richard Littlewood United Kingdom 12 238 2.5× 249 2.8× 35 0.7× 73 1.4× 39 0.8× 24 418
Lien‐Wen Su Taiwan 9 80 0.8× 98 1.1× 48 0.9× 8 0.2× 43 0.8× 16 298
Jörg Gölz Germany 9 162 1.7× 119 1.4× 23 0.4× 66 1.3× 30 0.6× 18 260
Samantha Lee United States 11 26 0.3× 58 0.7× 28 0.5× 8 0.2× 29 0.6× 33 271
Patricia Pade United States 7 81 0.9× 171 1.9× 42 0.8× 13 0.3× 100 2.0× 9 322

Countries citing papers authored by Fatemeh Chalabianloo

Since Specialization
Citations

This map shows the geographic impact of Fatemeh Chalabianloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatemeh Chalabianloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatemeh Chalabianloo more than expected).

Fields of papers citing papers by Fatemeh Chalabianloo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatemeh Chalabianloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatemeh Chalabianloo. The network helps show where Fatemeh Chalabianloo may publish in the future.

Co-authorship network of co-authors of Fatemeh Chalabianloo

This figure shows the co-authorship network connecting the top 25 collaborators of Fatemeh Chalabianloo. A scholar is included among the top collaborators of Fatemeh Chalabianloo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fatemeh Chalabianloo. Fatemeh Chalabianloo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lundervold, Astri J., Berit Skretting Solberg, Anders Engeland, et al.. (2025). Prevalence of substance use disorder in individuals with attention deficit/hyperactivity disorder: associations with sex and psychiatric comorbidity. BMC Psychiatry. 25(1). 936–936. 1 indexed citations
3.
Madebo, Tesfaye, et al.. (2025). Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy. JAMA Psychiatry. 82(4). 406–406.
4.
Eum, Seenae, et al.. (2024). Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism & Toxicology. 21(3). 289–304.
5.
Vold, Jørn Henrik, Fatemeh Chalabianloo, Else‐Marie Løberg, et al.. (2024). Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders. Scientific Reports. 14(1). 816–816.
6.
Vold, Jørn Henrik, Fatemeh Chalabianloo, Else‐Marie Løberg, et al.. (2023). The efficacy of integrated hepatitis C virus treatment in relieving fatigue in people who inject drugs: a randomized controlled trial. Substance Abuse Treatment Prevention and Policy. 18(1). 25–25. 1 indexed citations
7.
Chalabianloo, Fatemeh, Lars Thore Fadnes, Kjell Arne Johansson, et al.. (2023). Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Basic & Clinical Pharmacology & Toxicology. 134(3). 333–344. 1 indexed citations
8.
Narasimha, Venkata Lakshmi, Enjeline Hanafi, Mehdi Farokhnia, et al.. (2022). Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. BJPsych International. 19(3). 66–69. 8 indexed citations
9.
Chalabianloo, Fatemeh, et al.. (2021). Effectiveness and Safety of Low-Threshold Opioid-Agonist Treatment in Hard-To-Reach Populations with Opioid Dependence. European Addiction Research. 28(3). 199–209. 9 indexed citations
10.
Fadnes, Lars Thore, Christer Frode, Jørn Henrik Vold, et al.. (2021). Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Medicine. 18(6). e1003653–e1003653. 38 indexed citations
11.
Chalabianloo, Fatemeh, Lars Thore Fadnes, Gudrun Høiseth, et al.. (2021). Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. Substance Abuse Treatment Prevention and Policy. 16(1). 39–39. 7 indexed citations
12.
Vold, Jørn Henrik, et al.. (2021). Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. Substance Abuse Treatment Prevention and Policy. 16(1). 67–67. 5 indexed citations
13.
Frode, Christer, Jørn Henrik Vold, Svetlana Skurtveit, et al.. (2020). On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open. 10(8). e036355–e036355. 4 indexed citations
14.
Vold, Jørn Henrik, Rolf Gjestad, Fatemeh Chalabianloo, et al.. (2020). Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. Substance Abuse Treatment Prevention and Policy. 15(1). 93–93. 8 indexed citations
15.
Welle-Strand, Gabrielle K., et al.. (2020). Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy. Journal of Substance Abuse Treatment. 113. 108004–108004. 7 indexed citations
16.
17.
Vold, Jørn Henrik, Svetlana Skurtveit, Ingvild Odsbu, et al.. (2020). Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017. BMC Psychiatry. 20(1). 119–119. 7 indexed citations
18.
Chalabianloo, Fatemeh, Andreas Austgulen Westin, Eirik Skogvoll, Jørgen G. Bramness, & Olav Spigset. (2019). Methadone serum concentrations and influencing factors: A naturalistic observational study. Psychopharmacology. 236(11). 3159–3167. 8 indexed citations
19.
Fadnes, Lars Thore, Christer Frode, Jørn Henrik Vold, et al.. (2019). Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infectious Diseases. 19(1). 943–943. 25 indexed citations
20.
Chalabianloo, Fatemeh. (2012). Hypersensitivitet ved bruk av ikke-steroide antiinflammatoriske legemidler. Tidsskrift for Den norske legeforening. 132(17). 1961–1963. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jørn Henrik Vold Breakdown of academic impact, for papers by Richard Hallinan Breakdown of academic impact, for papers by Oscar D’Agnone Breakdown of academic impact, for papers by Elise Bailey Breakdown of academic impact, for papers by Nuria J. Thusius Breakdown of academic impact, for papers by Richard Littlewood Breakdown of academic impact, for papers by Lien‐Wen Su Breakdown of academic impact, for papers by Jörg Gölz Breakdown of academic impact, for papers by Samantha Lee Breakdown of academic impact, for papers by Patricia Pade
Rankless by CCL
2026